Navigation Links
Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
Date:11/4/2008

HAE: TSX

MONTREAL, Nov. 4 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE) announced today that Joseph Galli, Chairman and Chief Executive Officer of Haemacure, will present at the Rodman and Renshaw Annual Global Investor Conference being held November 10-12 in New York. Mr. Galli will present a corporate progress report, including an update on the Company's lead product candidate, Hemaseel(R)HMN (fibrin sealant). The Haemacure presentation is scheduled to begin at 3:15 p.m. local time on Monday, November 10th.

The Haemacure presentation will be webcast live and may be accessed by clicking on the following link: http://www.wsw.com/webcast/rrshq14/hae.cn. The presentation will also be available on the Haemacure website, http://www.haemacure.com, for a limited time following the conference.

Additional information on the Rodman and Renshaw Annual Global Investor Conference is available at http://www.rodmanandrenshaw.com/conferences.

Please visit the site at least five minutes prior to start time for instructions.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first half of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on the use of its fibrin sealant in adhesion prevention, aesthetics, combination with
'/>"/>

SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
3. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
4. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
5. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
6. Haemacure Reports on its annual general and special meeting of shareholders
7. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
8. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
9. Haemacure financing receives shareholder consent - Series B Warrants are amended
10. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., Eating high amounts of salt is linked to a sign...r disease, states a paper published today in the ...ried out jointly by the World Health Organization,... University of Warwick and University Hospital in ...sion Excellence Centre in Hypertension based at th...
(Date:11/24/2009)... (Boston) Researchers from Boston University Scho...omedical Engineering Department have identified a ... distinguish between cancer and normal cells with ...searchers have developed a new computational strat... key biological pathways (molecular circuits) that...
(Date:11/24/2009)..., DALLAS,Nov.24/PRNewswire-USNewswire/--TheBa...erofoneofthelargestcancerclinicaltrialscooperative...theNationalCancerInstitute,SouthwestOncologyGroupc...ts,andtoimprovethequalityoflifeforcancersurvivors....feradditional,importantclinicaltrialstocancerpatie...
(Date:11/24/2009)..., LAKESUCCESS,N.Y.,Nov.24/PRNewswire-USNewswi...ation,aninternationalqualitymanagementstandardfocu...mersatisfactionandcontinuallyimprovingbusinessperf...nalCertificationServicesmeansIPRO,sQualityManageme...assingoperationsatitsofficesinLakeSuccessandAlbany...
(Date:11/24/2009)... The molecular cause of in...esearch will be presented at the upcoming 2009 Adv...quo;s & Colitis Foundation’s Clinical &a..., Florida, that may identify a causative mutation ... New York, NY (Vocus) November 24, 2009 -- The ...
Breaking Medicine News(10 mins):Health News:High salt intake linked to strokes and cardiovascular disease 2Health News:Researchers identify proteins in lung cancer cells that may provide potential drug targets 2Health News:Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups 2Health News:IPRO Earns Third Consecutive Quality Management Certification 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4
...COLUMBUS, Ohio, Nov. 2 GSW Worldwide, an inVentiv...rgest healthcare advertising,agencies in the world...,Diagnostics Company (BioBDx) for their McLean Mot...on Deficit,Hyperactivity Disorder (ADHD). GSW Wor...
...WILMINGTON, Del., Nov. 2 Staff and board,members ...ief Executive,Officer, Susan D. Lloyd, MSN, RN, fo...ion Dinner., Since 1987, Susan Lloyd has guided D... and compassion., In 1987, the five-year old Dela...
...WOODCLIFF LAKE, N.J., Nov. 2 Barr,Pharmaceuticals...idiary, Barr,Laboratories, Inc., has initiated a c...euticals Corporation in connection with its Ritali...containing a,paragraph IV certification for a gene...
...EmployeeElect will offer flexibility and cost-cont...rs in Maine,now have the health insurance options ...lue Shield announced today a new portfolio of elev...ce,choices than have ever been available for Maine...
...Data Expanded for Oncology, Neurology and Urology;... and OB/GYN, MOUNT LAUREL, N.J., Nov. 2 ImpactRx...ct of pharmaceutical promotion on,physicians, pres...ng client demand. ImpactRx is increasing the size ...
...WEST BRIDGEWATER, Mass., Nov. 2 Pressure,BioScien... that Richard T.,Schumacher, PBI Founder, Presiden...he Rodman & Renshaw Acumen BioFin 9th Annual Healt...ork,City. The Company,s audio portion and slides o...
Other Medicine News:Health News:GSW Worldwide Named Agency of Record for BioBehavioral Diagnostics Company's MMAT/ADHD(TM) System 2Health News:GSW Worldwide Named Agency of Record for BioBehavioral Diagnostics Company's MMAT/ADHD(TM) System 3Health News:Delaware Hospice Honors President and CEO Susan D. Lloyd, MSN, RN 2Health News:Delaware Hospice Honors President and CEO Susan D. Lloyd, MSN, RN 3Health News:Barr Confirms Patent Challenge of Ritalin(R) LA 2Health News:Barr Confirms Patent Challenge of Ritalin(R) LA 3Health News:Anthem Introduces New Insurance Options for Small Business 2Health News:ImpactRx Announces Expansion and Addition of Physician Information Networks 2Health News:ImpactRx Announces Expansion and Addition of Physician Information Networks 3Health News:Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th 2
(Date:11/24/2009)...if.,Nov.24/PRNewswire-FirstCall/--IPCTheHospitalis...talistphysiciangrouppracticecompany,announcedtoday...medby ACPHospitalist asoneofthe2009TopTenHospitali...ueofthemagazine. ,, Dr.Vaidyanhasbeenapracticin...rectorofhospitalmedicineatSt.Mary,sHealthCenterinS...
(Date:11/24/2009)...PRNewswire/--MAQUETCardiovascularLLC,aleadingprovi...ithassignedaguaranteedtwo-yearcontractwithNovation...ns,tobethesolesourceproviderofsurgicaldevicesforbe...agreement,whichrunsthroughOctober31,2012,MAQUETCar...tdevicesanddisposablesuppliestothemembersofVHAInc....
(Date:11/24/2009)....,Nov.24/PRNewswire/--SatelliteHealthcare,oneofthe...rvicesandamajorsponsorofnephrologyresearch,todayan...EliasNasrallahinhisefforttosupporttheSanJosehomele...ltasuccessfulcareerasachefforthepast20years.ButNas...ewasdiagnosedwithEndStageRenalDisease(ESRD).Thedia...
Breaking Medicine Technology:IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices 2MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices 3Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 2Veran Medical Enables Breakthrough 4D Navigation to Cancer Lesions at University of Virginia Hospital 49893 1Veran Medical Enables Breakthrough 4D Navigation to Cancer Lesions at University of Virginia Hospital 49893 2Stay Upbeat Active to Keep the Mind Young 49889 1Stay Upbeat Active to Keep the Mind Young 49889 2Stay Upbeat Active to Keep the Mind Young 49889 310th CyberKnife System Installed at an HCA Hospital 49885 110th CyberKnife System Installed at an HCA Hospital 49885 210th CyberKnife System Installed at an HCA Hospital 49885 310th CyberKnife System Installed at an HCA Hospital 49885 4
...een across range of,patient populations, including...igh risk of developing diabetes , * Galvus lowers ...ing efficacy in combination with commonly used dia... in humans with studies showing,incidence of side ... * European regulatory decision anticipated by end...
...ents in Blood Glucose,Control and Progressive Weig...tCall/ -- Amylin,Pharmaceuticals, Inc. and Eli Lil...y that showed BYETTA(R) (exenatide) injection,sust...essive weight,loss through three and a half years ...ith improvements in cardiovascular risk,factors in...
Other Medicine Technology:New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 2New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 3New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 4New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 5New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 6Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6
...a pistol-grip handpiece available in Pneumatic, El...plers that can be used in a variety of orthopedic ...XT offers significantly increased torque and speed... Battery SmartDriver XT accepts the full line of S...
...ietary PolyGraft® material technology which pr...iologically friendly and biomechanically stable. ...calcium sulfate and polyglycolide fibers, the Poly...s such as granules, blocks, wedges and other prefo...
...resents the most widely accepted "table fixed" ret...ion components provides numerous surgical special... exposure of the surgical field.,Assembly is easy... before or during the procedure, thus saving valua...
Tipack (Sterilized) D1000
Medicine Products: